We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Interesting analysis Thoth. Lets hope you are right as it makes sense. Remember you making that call and you nailed it. Did not realise he was trying to get SRA into trials. It would change my view of him.
Rmm. Excellent analysis. I actually listened to nick glover on one of his last analyst calls. When i opined he would be out of a job soon. The reason is he was almost pleading for 10m to progress 737 and the investors felt hed had enough cash. Change of ceo and gilead on board since. I suspect sierra are analysing the data. Will represent and take forward internally. If the get an expedited approval on the data that would be expedited milestones to us as well (much larger than the 5m we are waiting for. Its a pain waiting. But news is due
RMM, I hear the sound of of distant drums, far away, far away, as it goes in the old Jim Reeves song. Keep banging it. Don't know what SIERRA are up to exactly but it sounds that the are beset by a paralysing fear that they will go to the wall. So why then did they boot out Mr No Good and end up with an apparent clone Mr Dilly Dally and, for what I believe from here to be, a pot of Gold.
Unless there is something going on behind the scenes, that we on here are not privy to, it would appear that there is a great moral wrong being played out before us. A likely treatment/cure for ano-genital, with unmet need lying idly by, while so many people suffer and die from this terrible disease, not to mention the highly successful combination treatments for other forms of cancer. Those who are responsible should one day be taken to account for their hair brained decisions. Time for those who have an interest in SRA737 to get the finger out and to insist on it's return. Making it wholly incredible is the fact that SRA737 would be , by all accounts a far better commercial opportunity than Momelot. Would be great if the distant drums made their way into newspaper headlines.
Hi RMM - please keep banging on!
Doesn't this not all hinge on whether Sierra have made 'Commercially Reasonable Efforts' to develop SRA737 in a diligent and timely manner as defined by the contract. If they haven't then the asset returns to ICR/Sareum via CRT. It is simply implausible that Tim et al don't know precisely what's happening.
GLA
SRA737 is no interest to Sierra, they have had enough time to find a resolution and the new director hasn’t changed that focus on Momelotinib, what they want is not just to give it back because of the development time/cost they put into it, until they find somebody willing to license, I think Covid short term has made it hard to find one with the pharma market resources lent towards this!
RMM3383, keep banging the drum and let the professionals decide the value of 737.
Not expecting anything today / tomorrow but time will tell. Someone or several individuals must be in possession of the outcome of the recent trials.
If 737 was of no interest to Sierra then we'd have it back by now. It didn't stop them handing back 141. As to banging the drum, I'd much rather have the milestones to 737 than a £50-100k grant for Covid. The latter will be on a parr with the Aurora payment earlier this year and that didn't lead to a re-rate. £5m in the bank will signficantly impact the SP. But that's just my preference. I'll put the drum back in the cupboard if that's what everyone wants.
I agree with you ab, so that's why I don't understand this constant expectation that sirerra are about to drop so need of a deal
So Utah - if of very little interest what are ICR etc doing legally about getting it back under trials with someone else ? ... thats where the frustration lies with everyone ... hence the drum banging should not stop till resolution obtained ... feels almost like the management teams cant even find the bloody brewery ... pathetic IMHO
737 is of very little interest to SIerra, why can't people just accept that short term instead of keep banging that drum?
Irrespective of who is in the driving seat on the contract with Sierra there is no avoiding the fact that we are due news. Sierra have recently presented at two conferences and released their Q3 2020 update. The focus at all off these events remains on Momelot. Under the leadership of NG all the eggs were put into one basket (737 and 141 sidelined). 141 has been handed back with a few caveats on royalties if it ever makes the grade while 737 remains within the Sierra portfolio, even if hidden. From a strategic perspective the focus on Momelot is not going to excite investors - a global market size of currently <$1bn which when compared with the market size of anogenital ($16bn and growing at 6.46% pa) is small. Even anal cancer on its own is as big as the Myelofibrosis market. NG pursued Momelot because it was the asset closest to commercialisation. However, the delays in getting it approved mean no headline data before the middle of 2022, assuming the trials are not significantly delayed by Covid. Meanwhile they retain an asset with an unmet need in a market with a much bigger value and which will be approaching $18bn by the time Momelot gets to market. In Stephen Dilly's shoes I would be fighting tooth and nail to keep my hands on 737. Momelot is not exciing the Sierra investors (SP down another 6% aftert yesterday's conference paper) so he needs to do something to stabilise the SP because Momelot is not going to come to his rescue for at least 2 years. Whether its Gilead or ANO I don't believe they're not talking actively to a non-diluting partner. Whatever is going on we need an update but if its NDA'd then we can but wait. What SAR/ICR et al can do is clarify the contractual terms on 737 coming back to us and the timeline. On a different tack, many thanks to Zylo for the link to the Covid grants. Good to see money well spent! £89k to the University of Plymouth to look at poets collaborating internationally on the topic. Anything less than that to SAR for a therapeutic treatment would be an insult but then the Government has put the hopeless Baroness Harding in charge of Track and Trace.... God help us. GLA all LTH's